natgillin/translations-raw huggingface dataset:
It is worth noting that the above reported concentrations represent the “apparent assays” of the compositions, which actually—if obtained according to literature procedures, particularly by concentration through urea complexing and if not submitted to additional careful phase of purification—are always undoubtedly contaminated by substantial quantities of “oligomers” as above defined and by other impurities. 
Valja primijetiti da gore navedene koncentracije predstavljaju "očigledne udjele" pripravaka, koje su zapravo - ako su dobivene po postupcima iz literature, naročito koncentriranjem pomoću kompleksiranja s ureom i ako nisu podvrgnuto dodatnoj pažljivoj fazi pročišćavanja - su uvijek nesumnjivo zagađene znatnim količinama "oligomera", kako je gore definirano, i drugim onečišćenjima.
The reaction mixture was cooled in an ice-water bath and a solution of NH4OAc in MeOH (15mL) was added followed by the addition of IPAc (50mL) and H2O (20mL). 
Reakcijska smjesa je bila ohlađena u kupelji led-voda i otopina NH;OAc u MeOH (15 mL) bila je dodana i nakon toga je bio dodan IPAc (50 mL) i H2O (20 mL).
The method of claim 1, wherein the receiver (1) records on local storage possible media items that match profile data associated with the receiver (1). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što prijemnik (1) snima u lokalni spremnik moguće medijske točke koje odgovaraju podacima o profilu povezanim s prijemnikom (1).
The use as claimed in claim 11, wherein said therapeutic dose is at least 5 milligrams of aminopyridine. 
Upotreba prema zahtjevu 12, naznačena time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 5 do 10 miligrama aminopiridina.
An electrical connection system for a battery of an at least partially electric vehicle, the electrical connection system comprising a first electrical connector configured to permanently attach to an underside of the vehicle and a second electrical connector configured to permanently attach to a battery, the first and second electrical connectors being configured to be removably coupled to each other, wherein at least one of the first and second electrical connectors (2402, 2452) comprises: 
Sustav kliznih vrata (700) za omogućavanje pristupa donjoj strani vozila koji obuhvaća: vrata (704) koja klize u prvom smjeru; i pokretni sustav (706) u vratima koji klizi u drugom smjeru koji je suprotan prvom smjeru dok podupire barem jedan kotač vozila.
Preferred compositions and preparations of the present invention may be determined by methods well known to the skilled artisan. 
Poželjne pripravke i pripravke prema ovom izumu može se odrediti postupcim dobro poznatim stručnjaku.
The device according to claim 1, characterized in that said flat perforated plate (35) comprises at least two baffles (38). 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što navedena ravna perforirana ploča (35) ima najmanje dvije pregrade (38).
to 99 weight % neutral phospholipid and 1 to 5 weight % negatively charged phospholipid; or 
do 99 masenih % neutralnog fosfolipida i 1 do 5 masenih % fosfolipida s negativnim nabojem; ili
determining and sending corresponding information to the server system controlling the waste collection system; and 
određivanje i slanje odgovarajuće informacije u serverski sustav (100) koji nadzire sustav prikupljanja otpada (10); i
Basic design of equipment depends on the process design but the detailed equipment design can be different in order to meet PED, ASME or other local design codes or local state of the art technology. A method to store or increase the energy content of a reaction mixture by heating a reaction mixture comprising an inorganic oxoacid compound and/or its salt and water to cause an endothermic condensation reaction using heat from a heat source distinct from said reaction mixture. 
HR P20160021 T1 PATENTNI ZAHTJEVI Postupak za skladištenje ili povećanje sadržaja energije reakcijske smjese, pri čemu je spomenuta reakcija omogućena dovođenjem energije iz izvora topline koji nije identičan sa spomenutom reakcijskom smjesom, naznačen time što se sadržaj energije reakcijske smjese skladišti ili povećava endotermnom reakcijom kondenzacije, pri čemu spomenuta reakcijska smjesa sadrži neorganski oksokiselinski spoj i/ili njegovu sol i vodu.
A chimeric monoclonal anti-interleukin-32 (IL-32) antibody or IL-32 binding fragment thereof wherein the antibody or antigen-binding fragment thereof comprises in its variable regions the complementarity determining regions (CDRs) 
Humano monoklonsko anti-interleukin-32 (IL-32) protutijelo ili njegov fragment koji veže IL- 32, naznačeno time, da u svom teškom (VH) i varijabilnom lakom lancu (VL) sadržava komplementarnost koja određuje regije (CDR) VH-CDR1, VH-CDR2, VH-CDR3 a VL-CDR1, VL-CDR2 i VL-CDR3 su odabrani od
According to an alternative example (not shown), the apparatus 1 comprises a number of doors equal to the number of levels of the magazine 3, the movement system 5 is capable of rotating the whole magazine 3, and the processing system 7 is capable of releasing the opening of a single door at a time during normal operation. 
U skladu s jednim alternativnim primjerom (nije prikazan) ovaj uređaj 1 sadržava veći broj vrata koji je jednak broju nivoa spremnika 3, pri čemu sustav za pomicanje može rotirati cijeli spremnik 3, a sustav za obradu 7 može omogućiti u isto vrijeme otvaranje samo jednih vrata za vrijeme normalnog rada.
Tremor can be induced by administration of GYKI 20039 (3-(2,6-dichlorophenyl)-2-iminothiazolidine). 
Tremor se može izazvati davanjem GYKI-a 20039 (3-(2,6-diklorfenil)-2-imino-tiazolidin).
A sealed container according to embodiment 10, wherein the atmosphere within the sealed container has been modified or controlled. 
Posuda prema Zahtjevu 7, gdje je atmosfera unutar hermetički zatvorene posude izmijenjena ili kontrolirana.
The host cell of paragraph 57 wherein the host cell is E.coli. 
Stanica domaćin u skladu s patentnim zahtjevom 22, naznačena time što je stanica domaćin E. coli.
The base station apparatus according to claim 1, wherein said allocating unit maps, in the second allocation, Localized Virtual Resource Blocks (LVRBs) to PRBs, and allocates the LVRBs to the mobile station in units of the RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
The memory card of claim 1 wherein the transmit antenna and receive antenna are external to the memory card, the memory card comprising contacts to couple to the transmit antenna and receive antenna. 
Memorijska kartica prema zahtjevu 1, naznačena time da su antena za odašiljanje i prijamna antena jedna antena Memorijska kartica prema zahtjevu 1, naznačena time da je memorijska kartica mikro zaštitna digitalna (SD) kartica.
A composition comprising interleukin-2 and sodium dodecyl sulfate, wherein interleukin-2 and sodium dodecyl sulfate are present in the form of aggregates, and wherein the composition has one or more of the following characteristics: 
Sastav koji se sastoji iz interleukina-2 i natrijevog dodecil sulfata, naznačen time, da su IL-2 i natrijev dodecil sulfat prisutni u obliku agregata, i u čemu sastav ima jednu ili više sljedećih karakteristika:
The reaction mixture is concentrated under reduced pressure and the residue is quenched with water (7 mL). 
Reakcijsku smjesu koncentrira se pod sniženim tlakom, a ostatak ugasi vodom (7 ml).
If a flat surface is required, the body may be leveled or covered by applying an appropriate non-magnetic material to the surface. 
Ako je potrebna ravna površina, tijelo se može izravnati ili pokriti nanošenjem prikladnog nemagnctskog materijala na površinu.
contacting the first digested nucleic acid with a second nucleic acid, a double stranded joiner oligo, and an exonuclease, wherein the joiner oligo is a linear double-stranded DNA that is from about 50 bp to about 400 bp and comprises: 
dovođenje u kontakt prve digestirane nukleinske kiseline sa drugom nukleinskom kiselinom, dvolančanim spojnim oligonukleotidom, i egzonukleazom, pri čemu je spojni oligonukleotid predstavljen linearnom dvolančanom DNK od oko 50 bp do oko 400 bp i uključuje:
The antibody, or antigen-binding fragment thereof, of claim 1 or 2, wherein the heavy chain of said antibody, or antigen-binding fragment thereof, contacts amino acid residues in said proximal monomer, and wherein the light chain of said antibody, or antigen-binding fragment thereof, contacts amino acid residues in said proximal monomer and in said distal right monomer of said HA trimer. 
protutijelo, ili njegov ulomak koji veže antigen u kojem teški lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinskim ostatcima u navedenom proksimalnom monomeru, i pri čemu laki lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinskim ostatcima u navedenom proksimalnom monomeru i u navedenom distalnom desnom monomeru navedenog HA trimera; i
characterized by an X-ray powder diffraction pattern having peaks at 7.9, 8.1, 13.5, 14.6 and 25.2 degrees two theta±0.2 degrees two theta. 
Formula | *HBr naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu sa signalima na 7,9, 8,1, 13,5, 14,6 1 25,2 26
4 and a light chain variable domain of sequence comprising the amino acid sequence SEQ ID No. 
4 te varijabilnu domenu sekvencije lakog lanca koja sadrži aminokiselinsku sekvenciju SEQ ID No.
Hydroxyfunctional fatty acids exist in for example castor oil where the hydroxyl group is situated on the 12th carbon on ricinoleic acid. 
Hidroksilne funkcionalne skupine masnih kiselina postoje, na primjer, u ricinusovom ulju, u kojem se hidroksilna skupina nalazi na dvanaestom ugljiku na ricinoleinskoj kiselini.
A pharmaceutical composition comprising the antibody of any one of claims 1 to 4 or 12 to 17, or produced by the method of claim 11, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo prema bilo kojem od zahtjeva 1, 2 ili 10 do 15, ili protutijelo koje se može dobiti putem postupka prema zahtjevu 9, i farmaceutski prihvatljiv nosač.
A pharmaceutically acceptable liquid composition comprising 0.25% to 20% by weight arginine, 0.5% to 6% by weight carbidopa, 0% to 30% by weight N-methylpyrrolidone (NMP), 0% to 5% by weight polyvinylpyrrolidone (PVP), and 0% to 5% by weight of one or more water soluble antioxidants, wherein said composition is stable at 25°C for 48 hours or more. 
Farmaceutski prihvatljivi tekući pripravak koji sadrži arginin, levodopu i karbidopu, naznačen time, da pripravak sadrži najmanje 4% težinskih levodope, ima molarni omjer levodopa:arginin izabran iz 1:1.5 do 1:2.5, ima pH od 8.5 do 10, i stabilan je kod 25°C 48 sati ili više.
A high purity diaminophenothiazinium compound according to claim 2 or 3, which is obtainable by a method of synthesis comprising the steps of, in order: nitrosylation (NOS), in which an N,N-disubstituted-3-optionally substituted aniline, 1, is 4-nitrosylated to give said N,N-disubstituted-3-optionally substituted-4-nitrosyl aniline, 2: 
Diaminofenotiazinski spoj visoke čistoće prema zahtjevu 2 ili 3, naznačen time, da se može dobiti putem postupka sinteze koji obuhvaća sljedeće korake, po redu: nitrozilacija (NOS) u kojoj se N,N-disupstituirani-3-opcionalno supstituirani anilin, 1, 4-nitrozilira kako bi dobio navedeni N,N-disupstituirani-3-opcionalno supstituirani-4-nitrozil-anilin, 2:
In a certain embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 3; a heavy chain variable region CDR2 of SEQ ID NO: 10; a heavy chain variable region CDR3 of SEQ ID NO: 17; a light chain variable region CDR1 of SEQ ID NO: 24; a light chain variable region CDR2 of SEQ ID NO: 31; and a light chain variable region CDR3 of SEQ ID NO: 38. 
(b) CDRI varijabilno područje jakog lanca od SEQ ID NO:3; CDR2 varijabilno područje jakog lanca od SEQ ID NO: 10; CDR3 varijabilno područje jakog lanca od SEQ ID NO:17; CDRI varijabilno područje slabog lanca od SEQ ID NO:24; CDR2 varijabilno područje slabog lanca od SEQ ID NO:31; i CDR3 varijabilno područje slabog lanca od SEQ ID NO:38; ili
Some illustrative examples of such cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. 
Neki tipični primjeri takvih cikloalkilnih skupina jesu ciklopropil, ciklobutil, ciklopentil 1 cikloheksil.
the vacuum interrupter (301) is a cylindrical vacuum interrupter, wherein the first center axis (304) is a first cylindrical axis; 
vakuumski prekidač (301) je vakuumski prekidač cilindričnog oblika, pri čemu je prva središnja os (304) prva cilindrična os;
Element according to claim 2, characterized in that it comprises a first elastic band (24), arranged to cross said free area (23) and connecting each other said arc shaped portions (22A), (22B). 
Element u skladu s patentnim zahtjevom 2, naznačen time, da sadržava prvu elastičnu traku (24), koja je postavljena tako da prelazi navedenu slobodnu površinu (23) i međusobno povezuju navedene dijelove u obliku luka (22A), (22B).
preparation of a 2-halozinc propionate ester according to formula (II) wherein X is bromide, iodide or chloride, in the presence of a solvent, at a temperature below the boiling temperature of the solvent, 
(ID pri čemu X je bromid, jodid ili klorid, u prisutnosti otapala, na temperaturi ispod temperature vrelišta otapala, (11) uvođenje ketona prema formuli (III)
The process of claim 1, wherein the resultant oxycodone hydrochloride composition comprises 14-hydroxycodeinone in an amount of less than 15 ppm. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 15 ppm.
number of trials 
broj ispitivanja
a first polyol, the first polyol being selected from mannitol, sorbitol or a combination thereof, and the concentration of the first polyol is at least 0.01 w/v% but no greater than 0.5 w/v%; 
prvi poliol, te je prvi poliol odabran od manitola, sorbitola ili njihove kombinacije, pri čemu je koncentracija prvog poliola najmanje 0,01 m/v% ali manja od 0,5 m/v%;
A form of rifaximin t, characterized in that it is a solvated form of rifaximin with diethylene glycol monoethyl ether. 
PATENTNI ZAHTJEVI Kristalni oblik T rifaksimina naznačen time što je solvatirani oblik rifaksimina s dietilen-glikol-monoetil-eterom.
generating at the processing unit (11) an electronic document comprising data related to the preceding steps, 
- < stvaranje elektronskog dokumenta u jedinici za obradu (11) koji sadrži podatak koji se odnosi na prethodni korak,
A bifunctional molecule comprising a polypeptide binding partner specific for a given pMHC epitope, and an immune effector polypeptide, the N-terminus of the pMHC binding partner being linked to the C-terminus of the immune effector polypeptide, PROVIDED THAT the said polypeptide binding partner is not a T-cell receptor comprising the alpha chain SEQ ID No: 7 and the beta chain SEQ ID No: 9. 
PATENTNI ZAHTJEVI Po ona m Bifunkcionalna molekula koja sadrži polipeptid vezujućeg partnera specifičnog za dani pMHC epitop, i imunološki efektorski polipeptid, gdje je N-kraj pMHC vezujućeg partnera vezan na C-kraj imunološkog efektorskog polipeptida, naznačena time što je polipeptid vezujući partner antitijelo.
The telescopic sight mount of claim 3, wherein a distance of each plane surface of the plurality of plane surfaces to a rotational axis of the adjusting wheel corresponds to a specific angle of forward tilt. 
Teleskopski nosač za ciljnik s podesivim nagibom prema naprijed prema zahtjevu 6, naznačen time što se specifični kut nagiba prema naprijed dodjeljuje svakoj udaljenosti površine ravnine do osi rotacije kotača za podešavanje (16).
p is 0 or 1 and when p is 0 then a direct bond is intended; 
p je 0 ili 1, te kada p je 0 tada je namjeravana direktna veza;
The step of exposing the applied ink or coating composition to the magnetic field of the body according to the invention corresponds, in the context of the present disclosure, to the step of bringing the coated or imprinted substrate, i.e. 
Korak u kojem se nanesena tinta ili smjesa za premazivanje izlažu djelovanju magnetskog polja tijela sukladno predmetnom izumu odgovara, u kontekstu predmetne specifikacije, koraku u kojem se premazana ili otisnuta podloga, tj.
The filter preferably inhibits ingress of particulate into the container. 
Raspršivač sukladno zahtjevu 1, pri čemu filtar sprječava ulazak čestica u spremnik.
a first composition forming an active agent-containing first layer of the extended release matrix formulation comprising: 
prvi pripravak koji tvori prvi sloj formulacije matrice s produljenim oslobađanjem koji sadrži aktivnu tvar koji sadrži:
The aqueous pharmaceutical suspension according to claim 7, wherein the benzyl alcohol is, by weight/volume (g/100 mL about 0.25% to about 1.00%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što benzil-alkohol iznosi, težinski/volumno (g/100 ml otprilike 0,25 % do otprilike 1,00 %.
The in vivo potency of the compounds of the invention was determined in a mature male castrated rat model. 
Potentnost spojeva prema ovom izumu in vivo određena je na odraslom kastriranom mužjaku štakora kao modelu.
A closure for a vial or a plunger for a hypodermic syringe according to claim 2 characterised in that the base thermoplastic elastomer is selected from the materials Evoprene™, Cawiton™, and C-Flex. 
Zatvarač za bočicu ili klip za potkožnu špricu u skladu s patentnim zahtjevom 2, naznačen time, što je osnovni termoplastični elastomer odabran od materijala EvopreneTM, CawitonTM i C-Flex.
Suppositories of the following composition are manufactured: 
Broj objave europskog patenta:
cardiac arrhythmia, preferably atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia (PSVT), premature atrial, nodal, or ventricular depolarizations, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes, 
(b) srčana aritmija, poželjno atrijalna fibrilacija, undulacija atrija, paroksizmalna supraventrikulska tahikardija (PSVT), preuranjena atrijalna, nodalna, ili ventrikulska depolarizacija, atrijalna tahikardija, ventrikulska tahikardija, ventrikulska fibrilacija, ili Torsades de Pointes,
For example, the cited review of 2003 by van Kesteren Ch. et al. reports that ET 743 has limited aqueous solubility. 
Na primjer, u citiranom prikazu van Kesteren Ch, et al iz 2003 navode da ET 743 ima ograničenu topljivost u vodi.
In a preferred embodiment of the preparation of the surface-reacted natural calcium carbonate, the natural calcium carbonate is reacted with the acid and/or the carbon dioxide in the presence of at least one compound selected from the group consisting of silicate, silica, aluminium hydroxide, earth alkali aluminate such as sodium or potassium aluminate, magnesium oxide, or mixtures thereof. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu prirodni kalcij karbonat reagira sa kiselinom i/ili ugljičnim dioksidom u prisutnosti barem jednog spoja izabranog iz skupine koja se sastoji od silikata, poželjno izabranog od aluminij silikata, kalcij silikata, ili zemno alkalnog metalnog silikata; silike, aluminij hidroksida, zemno alkalnog metalnog aluminata, magnezij oksida, ili njihovih smjesa.
A dimethanol solvate form of CDDO-methyl ester, having an x-ray powder diffraction pattern with characteristic peaks as shown in Table 18 and a DSC pattern as shown in Figure 24. 
Dimetanolni solvat CDDO-metilnog estera, naznačen time da čiji rendgenski difraktogram praha ima karakteristične maksimume kako je prikazano u Tablici 18 i DSC signal kako je prikazano u Slici 24.
or a salt thereof with a compound of formula (XI): 
HR P20090162 T1 ili njegove soli sa spojem formule (XI): coon o
A rodent according to any one of claims 1-14 further comprising at an endogenous rodent B2 microglobulin locus a nucleotide sequence encoding a polypeptide comprising a human B2 microglobulin amino acid sequence, wherein the rodent expresses a human or humanized B2 microglobulin polypeptide. 
Glodavac koji prema bilo kojem od zahtjeva 1. – 14. nadalje na endogenom lokusu B2 mikroglobulina glodavca sadrži nukleotidni slijed kojim se kodira polipeptid koji sadrži ljudski slijed aminokiselina B2 mikroglobulina, pri čemu glodavac izražava ljudski ili humanizirani polipeptid B2 mikroglobulina.
The nucleic acid molecule of claim 1, which is isolated. 
Vektor koji sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 3.
In one instance, X is selected from a monocyclic heteroaryl having 5 ring atoms selected from C, O, S and N provided the total number of ring heteroatoms is less than or equal to four and where no more than one of the total number of heteroatoms is oxygen or sulfur, and a monocyclic aromatic ring having 6 atoms selected from C and N provided that not more than 3 ring atoms are N, and where said ring may be optionally and independently substituted with up to two groups selected from C1-C4 alkyl, cycloalkyl, cycloalkyloxy, C1-C4 alkoxy, CF3, carboxy, alkoxyalkyl, C1-C4 cycloalkylalkoxy, amino, alkylamino, dialkylamino, amido, alkylamido, dialkylamido, thioalkyl, halogen, cyano, alkylsulfonyl and nitro. 
Spoj prema zahtjevu 4, naznačen time da je X opcionalno supstituirani prsten monocikličkog arila koji u prstenu ima pet atoma izabranih između C, O, S 1N, s time da je ukupni broj heteroatoma u prstenu manji od ili jednak četiri 1 da je najviše jedan od heteroatoma u prstenu kisik ili sumpor, naznačen time da je prsten heteroarila opcionalno i nezavisno supstituiran s najviše dva supstituenta izabrana iz skupine koju sačinjavaju C;-C4 alkil, C2C4 cikloalkil, C2-Cg cikloalkiloksi, Ci-C, alkoksi, CF2, karboksi, alkoksialkil, C,-Ca cikloalkilalkoksi, amino, alkilamino, dialkilamino, amido, alkilamido, dialkilamido, tioalkil, halogen, cijano, alkilsulfonil i nitro.
The immunogenic composition of claim 1 or 2 wherein the at least two further bacterial saccharide conjugates comprise a N. meningitidis capsular saccharide derived from a strain selected from the group consisting of serogroups A, B, C, W135 and Y. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis kojeg se dobiva iz soja kojeg se bira iz skupine koju čine seroskupine A, B, C, W135i Y.
The vectored vaccine of claim 15 wherein the viral vector expresses the translation product of the nucleotide sequence of SEQ ID NO: 5. 
Vektorsko cjepivo prema zahtjevu 15, gdje virusni vektor eksprimira produkt translacije nukleotidne sekvence od SEQ ID NO: 5.
A compound having a formula selected from the group consisting of: or wherein: 
Spoj formule koju se bira iz skupine koju čine:
8b-c and fig. 8d shows sections through the alternative base unit 3 and a corresponding alternative base part 5, respectively. 
Slike 8b-c i slika Sd prikazuju presjeke kroz alternativnu osnovnu jedinicu 3 i odgovarajući alternativan osnovni dio 5.
A method of preparing a liposome of irinotecan hydrochloride, comprising: preparing a blank liposome comprising a neutral phospholipid, polyethylene glycol 2000-distearoyl phosphatidyl ethanolamine, and cholesterol, wherein the weight ratio of the cholesterol to the neutral phospholipid is 1:4, and the neutral phospholipid consists of hydrogenated soybean phosphatidylcholine; 
Liposom prema zahtjevu 1, naznačen time što taj liposom sadrži sljedeće težinske omjere sastojaka: irinotekan hidroklorid 1 sojin hidrogenirani fosfatidilkolin 3,4-3,8 polietilen glikol 2000-distearoil fosfatidil etanolamin 0,34-0,38 kolesterol 0,8-0,95 i omjer kolesterola prema sojinom hidrogeniranom fosfatidilkolinu jest 1: 4.
identifying the peptide of which CTL inducibility is the same as or higher than the one of a peptide consisting of the original amino acid sequence. 
identificiranja peptida čija je inducibilnost citotoksične T-stanice ista kao ili veća nego kod peptida koji ima izvorni aminokiselinski slijed.